Diagnostic tests and prognostic indicators

Diagnostic accuracy of computed tomography-guided biopsy in pathological fractures. Stokes CM et al. ANZ J Surg. 2017 Mar 17. doi: 10.1111/ans.13894. [Epub ahead of print]. Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma. Dutoit JC et al. Skeletal Radiol. 2017 Mar 13. doi: 10.1007/s00256-017-2609-6. [Epub ahead of print]. CXCR4 (CD184) expression on stem cell harvest and…

Details

Related conditions

POEMS Syndrome: an Enigma. Warsame R et al. Curr Hematol Malig Rep. 2017 Mar 15. doi: 10.1007/s11899-017-0367-0. [Epub ahead of print]. Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept. Ramirez-Alvarado M et al. Am J Hematol. 2017 Mar 10. doi: 10.1002/ajh.24717. [Epub ahead of print]. The risk of renal disease is increased in…

Details

Emerging treatments

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Shah N et al. Br J Haematol. 2017 Mar 14. doi: 10.1111/bjh.14570. [Epub ahead of print]. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Sborov DW et al. Leuk Lymphoma. 2017 Mar 7:1-9. doi: 10.1080/10428194.2017.1298751.…

Details

Biology and genetics

p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. Tessoulin B et al. Blood Rev. 2017 Mar 4. pii: S0268-960X(16)30059-5. doi: 10.1016/j.blre.2017.03.001. [Epub ahead of print]. Mesenchymal stromal cells enhance the suppressive effects ofmyeloid-derived suppressor cells of multiple myeloma. Xu Y et al. Leuk Lymphoma. 2017 Mar 20:1-9. doi: 10.1080/10428194.2017.1298753. [Epub ahead of print]. Identification of…

Details

General

Update on the optimal use of bortezomib in the treatment of multiple myeloma. Mohan M et al. Cancer Manag Res. 2017 Mar 2;9:51-63. doi: 10.2147/CMAR.S105163. eCollection 2017. Multiple Myeloma: Diagnosis and Treatment. Michels TC et al. Am Fam Physician. 2017 Mar 15;95(6):373-383. Monoclonal antibody therapy in multiple myeloma. Touzeau C et al. Leukemia. 2017 Mar 10. doi: 10.1038/leu.2017.60. [Epub ahead of print]. Patients with myeloma need more time…

Details

Supportive treatments

Reinforced cementoplasty using dedicated spindles in the management of unstable malignant lesions of the cervicotrochanteric region. Premat K et al. Eur Radiol. 2017 Mar 13. doi: 10.1007/s00330-017-4774-3. [Epub ahead of print]. Biosimilar Retacrit® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) – non-interventional study. Losem C et al. Onco Targets Ther. 2017 Feb…

Details

Complications of myeloma and its treatments

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. Sidana S et al. PLoS One. 2017 Mar 9;12(3):e0172996. doi: 10.1371/journal.pone.0172996. eCollection 2017. Late recurrence of autologous GvHD in a myeloma patient: a myth or diagnostic challenge? El-Jurdi N et al. Bone Marrow Transplant. 2017 Mar 20. doi: 10.1038/bmt.2017.20. [Epub ahead of print]. Long-term control of extensive refractory chronic…

Details

Current treatments

Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (“VCD-Lite”) in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma. Tuchman SA et al. J Geriatr Oncol. 2017 Feb 27. pii: S1879-4068(17)30030-9. doi: 10.1016/j.jgo.2017.02.004. [Epub ahead of print]. Carfilzomib containing combinations as frontline therapy for multiple myeloma: a meta analysis of 13 trials. Sheng Z et al. Eur J Haematol. 2017…

Details